CTRI/2015/05/005827已完成未知
A randomized, single center, double blind, two-period, crossover glucose clamp study to test for bioequivalence between two recombinant human mixed insulins, Wockhardtâ??s Wosulin 30R/70N (regular insulin human, 30 IU per ml /isophane suspension 70 IU per ml) and Novolin® 70/30, in healthy subjects
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 56
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Ba/be
入排标准
入选标准
- •1.Considered generally healthy upon completion of medical history, physical examination X-ray chest (PA view), ECG and biochemical investigations as judged by the Investigator.
- •2.Body Mass Index (BMI) between 18.0 and 27.0 kg/m2, inclusive.
- •3.Non-smoker, defined as no nicotine consumption for last six months.
- •4.Subjects who agreed for verbal and written consent to audio-visual recording of the discussion of consent process and agreed to provide the signed and dated informed consent before any trial-related activities. (Trial-related activities are any procedure that would not have been performed during normal management of the subject.).
- •5.Subjects with normal results of 2 hours Oral Glucose Tolerance Test (OGTT) performed at screening.
排除标准
- •1.Previous participation in this trial or other clinical trials within the last 90 days.
- •2.Clinically significant abnormal haematology or biochemistry screening tests, as judged by the Investigator. In particular, subjects with elevated liver enzymes (AST or ALT 2 times the upper limit of normal) or impaired renal function (elevated serum creatinine values above the upper limit of normal)
- •3.History/presence of disorder related to CVS, CNS, Respiratory tract, GIT, Endocrinology, Haematology, Immunological or any other systemic disorder including any serious systemic infectious disease, as judged by the Investigator.
- •4.History of any illness that, in the opinion of the Investigator, might confound the results of the trial or pose risk in administering the trial drug to the subject. In particular, subjects with significant cardiovascular disease, gross anaemia (or subject with haemoglobin level 12 gm/dl at screening) or hemoglobinopathy will not be eligible to participate in the trial.
- •5.History of alcohol or drug abuse in the past five years.
- •6.Any positive test for drugs of abuse and /or alcohol at screening.
- •7.Hepatitis B or C or HIV or VDRL positive.
- •8.Use of prescription drugs within 3 weeks prior to screening.
- •9.Use of non-prescription drugs, except routine vitamins, within 2 weeks prior to screening.
- •10.Mental incapacity, unwillingness or language barriers precluding adequate understanding or subject co-operation.
- •11.Blood donation of more than 500 ml within the last 12 weeks.
- •12.Unwilling to stay in the clinical unit for the required duration or consume the standard meal to be provided as per the protocol.
- •13.History of multiple and/or severe allergies to drugs or foods or a history of severe anaphylactic reaction.
- •14.Known or suspected allergy to trial product or related products.
研究者
相似试验
已完成
不适用
A single-center, randomized, double-blind, two-period cross-over study to investigate the effect of a single intravenous dose of rifampicin on the pharmacokinetics of ACT-246475 in healthy subjects.Acute myocardial infarctionNL-OMON46064Idorsia Pharmaceuticals Ltd14
已完成
不适用
A single-center, randomized, double-blind, two-period cross-over study to investigate the effect of rifampicin on the pharmacokinetics of clazosentan in healthy male subjects.NL-OMON45870Idorsia Pharmaceuticals Ltd14
已完成
不适用
Bio-equivalence study of Biphasic Insulin Aspart Injection (30/70)CTRI/2021/09/036601Wockhardt Bio AG14
已完成
1 期
Bio-equivalence study of Biphasic Insulin Aspart Injection (30/70)CTRI/2023/02/050076Wockhardt Bio AG56
已完成
不适用
A single-center, randomized, double-blind, double-dummy, placebo- and active-controlled, 4-way cross-over study to assess next-day driving performance following single and multiple evening administrations of ACT-541468 in middle-aged and elderly subjects.InsomniaNL-OMON48154Idorsia Pharaceuticals Ltd.56